<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00748046</url>
  </required_header>
  <id_info>
    <org_study_id>15303</org_study_id>
    <secondary_id>BC1-08</secondary_id>
    <nct_id>NCT00748046</nct_id>
  </id_info>
  <brief_title>Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton</brief_title>
  <official_title>Phase 1, Open-label, Single Ascending-dose Study to Assess Safety, Pharmacokinetics, Biodistribution and Radiation Dosimetry of Intravenous Doses of Alpharadin™ Injection (Radium-223 Chloride) in Patients With HRPC and Skeletal Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry
      and pharmacokinetics of three intravenous escalating dose levels of Xofigo (Alpharadin).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Within the U.S., the trial is conducted under an IND sponsored by Bayer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All safety data, including adverse events, occurrence of treatment-emergent adverse events, changes in laboratory variables, vital signs, ECG, physical examination, long term radiation toxicity, including results of bone marrow biopsy</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biodistribution, dosimetry and pharmacokinetics (whole body activity assessment, the counts in region-of-interest (ROIs) from anterior and posterior whole-body images, and the assay of activity in blood</measure>
    <time_frame>6 days after injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-treatment PSA effect: PSA decline, time to PSA progression after PSA response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment bone markers effect: Changes in bone marker values from pre- to post administration</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating tumor cells (CTCs) enumeration and role of molecular profiling of CTC in predicting sensitivity to treatment and treatment response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Metastases</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Radium-223 chloride (Xofigo, BAY88-8223)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive Radium-223 chloride as an escalating dose of either 50, 100 or 200 kBq/kg b.w. (0.0014, 0.0027 or 0.0054 mCi/kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radium-223 chloride (BAY88-8223)</intervention_name>
    <description>The required volume of study drug to be administered to a patient was calculated using the patient's body weight.</description>
    <arm_group_label>Radium-223 chloride (Xofigo, BAY88-8223)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be ≥18 years of age

          -  Have histologically or cytologically evidence of adenocarcinoma of the prostate

          -  Have progressive castrate metastatic disease as shown by at least one of the
             following:

               -  Imaging modalities:

                    -  Radionuclide Bone Scan: New osseous lesions

                    -  MRI or CT: At least a 20% increase in the sum of the LD of target lesions OR

               -  Biochemical progression: A minimum of three rising PSA values from a baseline
                  that are obtained 1 week or more apart, or 2 measurements 2 or more weeks apart

          -  Have skeletal metastases confirmed by bone scintigraphy within the last 4 weeks.
             Evidence of at least 2 bone metastases on bone scan.

          -  Have castrate levels of testosterone (&lt;50 ng/ml). Treatment to maintain castrate
             levels of testosterone must be continued.

          -  Patients who have failed initial hormonal therapy using either an orchiectomy or a
             GnRH agonist in combination with an antiandrogen must first progress through
             antiandrogen withdrawal prior to being eligible. The minimum timeframe to document
             failure of anti-androgen withdrawal will be four weeks.

          -  Have Karnofsky performance status ≥60%

          -  Have a life expectancy ≥6 months

          -  Have the following laboratory requirements:

               -  White Blood Count (WBC) ≥3,000/mm3

               -  Absolute Neutrophil Count (ANC) ≥1,500/ mm3

               -  Platelet (PLT) ≥100,000/ mm3

               -  Hemoglobin (HGB) ≥10 mg/dl

               -  Bilirubin ≤2.0 mg/dl (unless the patient has Gilbert's syndrome)

               -  AST and ALT ≤2,5 times upper institutional limit of the normal range

               -  Serum creatinine ≤2.0 mg/dl

          -  Must be able and willing to sign an informed consent indicating that he is aware of
             the investigational nature of this study in keeping with the policies of the
             institution and have provided written authorization for use and disclosure of
             protected health information

          -  Must be willing and able to comply with the protocol, and agrees to return to the
             hospital for follow-up visits and examination

        Exclusion Criteria:

          -  Have received an investigational drug within 4 weeks prior to the administration of
             Radium-223 chloride, or is scheduled to receive one during the treatment and
             post-treatment period

          -  Have received chemo-, immunotherapy, or external radiotherapy within the last 4 weeks
             prior to administration of study drug, or has not recovered from acute adverse events
             as a result of such therapy

          -  Have received prior hemibody external radiotherapy

          -  Have a need for immediate external radiotherapy

          -  Have received systemic radiotherapy with radium-223, strontium-89, samarium-153,
             rhenium-186 or rhenium-188 for the treatment of bony metastases within the last 24
             weeks prior to administration of study drug

          -  When receiving bisphosphonates, have changed the dose within 4 weeks before
             administration of study drug

          -  Have started or stopped systemic steroids within a week prior to study drug
             administration, or are expected to be subject to changes in the systemic steroid
             medication

          -  Have imminent or established spinal cord compression based on clinical findings and/or
             MRI

          -  Have other currently active (relapse within the last 3 years) malignancy (except
             non-melanoma skin cancer) that are not prostate cancer metastases

          -  Have small cell carcinoma

          -  Have predominant visceral metastases (≥ 3 lung or liver lesions) or symptomatic
             lymph-adenopathy (scrotal or pedal edema)

          -  Any other serious illness or medical condition, for example:

               -  any uncontrolled infection

               -  any patient who has clinical heart failure severe enough to cause marked
                  limitation of activity, and who is only comfortable at rest; or any patient who
                  has heart failure more severe than this (NYHA Heart Failure Class III or IV)

               -  Crohn's disease or ulcerative colitis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J. Morris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <results_reference>
    <citation>Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N, Humm JL, Rathkopf DE, Slovin SF, Williamson MJ, Lacuna K, Aksnes AK, Larson SM, Scher HI, Morris MJ. Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1384-93. doi: 10.1007/s00259-013-2427-6. Epub 2013 May 8.</citation>
    <PMID>23653243</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2008</study_first_posted>
  <last_update_submitted>June 24, 2014</last_update_submitted>
  <last_update_submitted_qc>June 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biodistribution</keyword>
  <keyword>Radiation dosimetry</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radium Ra 223 dichloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

